International Medical Insurance – Page 88

December 19, 2019

First Ebola Vaccine Approved

December 19, 2019 – The U.S. FDA has approved Ervebo® (Ebola Zaire Vaccine, Live) manufactured by Merck. It is the first vaccine in the world approved to prevent disease caused by Zaire ebolavirus, one of the organisms responsible for causing Ebola virus disease (EVD). The vaccine is indicated for use in

December 19, 2019

FDA Safety Communication for Gabapentin and Pregabalin

December 19, 2019 – The U.S. FDA has issued a warning that serious breathing difficulties may occur in patients who have respiratory risk factors and use the medications gabapentin or pregabalin. Risk factors include advanced age, respiratory diseases such as chronic obstructive pulmonary disease (COPD) that

December 19, 2019

Arazlo Approved to Treat Acne

December 19, 2019 – The U.S. FDA has approved ArazloTM (tazarotene) lotion 0.045%, manufactured by Ortho Dermatologics. The product is indicated to provide topical treatment of acne vulgaris in patients who are at least nine years of age. Although the active ingredient has been FDA approved since 1997

December 18, 2019

Padcev Approved to Treat Bladder Cancer

December 18, 2019 – The U.S. FDA has granted accelerated approval to PadcevTM (enfortumab vedotin- ejfv), manufactured by Astellas and Seattle Genetics, to treat adult patients who have locally advanced or metastatic urothelial cancer. Patients must have already been treated with a platinum

December 18, 2019

Glenmark Recalls Prescription Ranitidine

December 18, 2019 – Glenmark Pharmaceuticals has halted distribution of both its 150mg and 300mg prescription ranitidine tablets due to the potential for N-nitrosodimethylamine (NDMA) levels in excess of the FDA’s currently established limits. The company has also recalled all unexpired lots on the United

December 16, 2019

Xtandi Receives New Indication

December 16, 2019 – The U.S. FDA has approved a new indication for Xtandi® (enzalutamide), manufactured by Pfizer, to treat patients who have metastatic castration-sensitive prostate cancer (mCSPC). The product was first approved in 2012 and is also indicated to treat castration-resistant

December 13, 2019

Expanded Indication Approved for Tiglutik

December 13, 2019 – The U.S. FDA has approved an expanded indication for Tiglutik® (riluzole) oral suspension, manufactured by ITF Pharma. Under the expansion, the product can now be administered via percutaneous endoscopic gastrostomy (PEG) tubes to treat amyotrophic lateral sclerosis (ALS).

December 13, 2019

Vascepa Receives New Indication to Reduce Cardiovascular Risk

December 13, 2019 – The U.S. FDA has approved a new indication for Vascepa® (icosapent ethyl) capsules, manufactured by Amarin. The product is now indicated as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina